Eli Lilly Achieves Coverage of All Obesity Medicines by Major U.S. Pharmacy Benefit Managers
Eli Lilly (LLY) has secured coverage for its entire obesity medicine portfolio, including Zepbound and Foundayo, from all three major U.S. pharmacy benefit managers: Express Scripts, Optum Rx, and CVS Caremark. This milestone follows a reversal by CVS after previously excluding Zepbound in favor of Novo Nordisk's Wegovy. The development supports Lilly’s growth trajectory as it reported strong Q1 2026 earnings with $19.8 billion revenue.
Topics: CVS Caremark Eli Lilly Foundayo obesity drugs PBMs Zepbound